Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

Sponsor
Assiut University
Study ID
NCT06668753
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

Eligibility Criteria

Sex
ALL
Age
20 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To rule out the beneficial effect of SGLT2-I to reduce liver fat, and change in inflammatory markers (ALT, AST) in type 2 diabetic patients with non-alcoholic fatty liver disease. And its role in improvement of Albuminuria and CKD progression.

Key Dates

Start date
Nov 1, 2024
Status verified
Oct 2024
Primary completion
Sep 30, 2026
Completion
Jul 30, 2027

Study Design

Enrollment
114 participants (estimated)

Arms

  • Arm: patients
    Dapagliflozin or Empagliflozin 10 mg once daily for 6 months
  • Arm: controls
    patients with standard anti-proteinuric regimen

Primary Outcome Measure

effect of SGLT2-I on NAFLD [ Time Frame: baseline ]

Central Contacts